Evidence-Based Gastroenterology and Hepatology

3. Auflage 2010
ISBN: 978-1-4051-8193-8
Verlag: Wiley-Blackwell

Buch, Englisch, 824 Seiten, Format (B × H): 230 mm x 285 mm, Gewicht: 2520 g

Reihe: Evidence-Based Medicine

The only evidence-based resource combining gastroenterology and hepatology, this major textbook critically appraises the evidence for diagnosis, screening, and treatment of gastrointestinal and hepatic diseases, and provides clear recommendations for management.

A unique feature is the grading of both the evidence (randomized controlled trials, systematic reviews, or lower quality trials) and the treatment recommendations. This structure provides the reader with valuable guidance on implementation.

The third edition has been fully revised, providing the latest reviews of the evidence. It is also enhanced with new topics that have significant evidence for treatment, including;
* Esinophilic esophagitis
* Acute dysenteries
* Prevention and treatment of travellers' diarrhoea
* Frequency of adverse drug effects on bowel function
* Management of hepatitis B
* Management of Hepatitis C
* Vascular disorder of the liver
* Non invasive diagnosis of liver fibrosis
* Drug induced liver disease

Autoren/Hrsg.

Mcdonald, John

McDonald, John

Burroughs, Andrew

Feagan, Brian

Fennerty, M. Brian

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Gastroentereologie, Proktologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hepatologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Evidenzbasierte Medizin (EbM)

Inhaltsverzeichnis

Part One.

Gastrointestinal Disorders.

1 Gastroesophageal reflux disease.

2 Barett's esophagus.

3 Esophageal motility disorders: achalasia and spastic motor disorders.

4 Esinophilic esophagitis.

5 Ulcer disease and helicobacter pylori.

6 Non-steroidal anti-inflammatory drug-induced gastroduodenal and enteric toxicity.

7 Non-variceal gastrointestinal hemorrhage.

8 Functional dyspepsia.

9 Celiac disease.

10 Crohn's disease.

11 Ulcerative colitis.

12 Pouchitis after restorative proctocolectomy.

13 Microscopic colitis: collagenous and lymphocytic colitis.

14 Drug induced Diarreha.

15 Metabolic bone disease in gastrointestinal disorders.

16 Colorectal cancer in ulcerative colitis: surveillance.

17 Colorectal cancer: population screening and surveillance.

18 Prevention and treatment of travellers' diarrhoea.

19 Clostridium difficile disease.

20 Irritable bowel syndrome.

21 Ogilvie's syndrome.

22 Gallstone disease.

23 Acute pancreatitis.

24 Obesity.

Part Two Liver disease.

25 Hepatitis C.

26 Hepatitis B.

27 Alcoholic liver disease.

28 Non-alcoholic fatty liver disease.

29 Hemochromatosis.

30 Wilson disease.

31 Primary biliary cirrhosis.

32 Autoimmune hepatitis.

33 Primary sclerosing cholangitis.

34 Non histological assessment of hepatic fibrosis.

35 Portal hypertensive bleeding.

36 Hepatic outflow syndromes and splanchnic venous thrombosis.

37 Ascites, hepatorenal syndrome and spontaneous bacterial peritonitis.

38 Hepatic encephalopathy.

39 Hepatocellular carcinoma.

40 Acute liver failure.

41 Liver transplantation: prevention and treatment of rejection.

42 Liver transplantation: prevention and treatment of infection.

43 Management of HCV infection and liver transplantation.

44 Management of HBV infection and liver transplantation.

45 Liver biopsy.

46 Drug induced liver disease - mechanisms and diagnosis

Über Autor(innen)

John McDonald, Professor of Gastroenterology at the University of Ontario, London Ontario, Coordinating Editor in the Cochrane Collaboration Steering Committee on methodology, and Past President of the Canadian College of Gastroenterology

Professor Andrew Burroughs MBChB Hons FRCP
Consultant Physician and Hepatologist, Royal Free Hospital, London, has an international reputation as a clinical and academic Hepatologist and has published widely in all areas of liver disease. He is a full time clinician and has been awarded a personal chair, as Professor of Hepatology in the University of London.

Brian Feagan is Professor of Medicine and Epidemiology and Biostatistics at the University of Western Ontario. He holds cross-appointments in the Divisions of Internal Medicine, Clinical Pharmacology and Gastroenterology. He is a specialist in Internal Medicine with training in Clinical Epidemiology and Gastroenterology who has been the lead investigator in the design and implementation of randomized controlled trials since 1986. In addition to being an internationally recognized expert in the therapy of Inflammatory Bowel Disease, Dr. Feagan has conducted trials on behalf of Industry and peer-reviewed agencies in a wide range of disease states. Dr. Feagan is interested in the evaluation of Health Related Quality of Life (HRQL) and has performed research on the operating properties of HRQL instruments.